SEC Form 10-Q filed by Achieve Life Sciences Inc.
$ACHV
Biotechnology: In Vitro & In Vivo Diagnostic Substances
Health Care
Unavailable
Unavailable
Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 8/21/2025 | $12.00 | Buy | H.C. Wainwright |
| 11/14/2024 | $12.00 | Buy | Rodman & Renshaw |
| 9/27/2024 | $20.00 | Strong Buy | Raymond James |
| 5/10/2023 | $8.00 → $20.00 | Buy | Maxim Group |
| 10/4/2021 | $25.00 | Buy | Alliance Global Partners |
| 6/23/2021 | $23.00 | Outperform | Oppenheimer |
8-K - ACHIEVE LIFE SCIENCES, INC. (0000949858) (Filer)
10-Q - ACHIEVE LIFE SCIENCES, INC. (0000949858) (Filer)
8-K - ACHIEVE LIFE SCIENCES, INC. (0000949858) (Filer)
SEATTLE and VANCOUVER, British Columbia, Sept. 18, 2025 (GLOBE NEWSWIRE) -- Achieve Life Sciences, Inc. (NASDAQ:ACHV), a late-stage specialty pharmaceutical company focused on the global development and commercialization of cytisinicline for treatment of nicotine dependence for smoking cessation, today announced the promotion of Craig Donnelly to Chief Operations Officer. Mr. Donnelly has been with Achieve since 2022, serving as Executive Vice President, Chemistry, Manufacturing, and Controls (CMC) and Regulatory CMC. In his expanded role as Chief Operations Officer, Mr. Donnelly will lead the integration of Achieve's supply chain and manufacturing activities with the commercial strategy
SEATTLE and VANCOUVER, British Columbia, Sept. 11, 2025 (GLOBE NEWSWIRE) -- Achieve Life Sciences, Inc. (NASDAQ:ACHV), a late-stage specialty pharmaceutical company focused on the global development and commercialization of cytisinicline for treatment of nicotine dependence for smoking cessation, today announced Mark Rubinstein, M.D., will assume the role of Interim Chief Medical Officer (CMO). Dr. Rubinstein will succeed Cindy Jacobs, Ph.D., M.D., who we anticipate will provide advisory services to support the company's ongoing efforts to advance cytisinicline as a potential treatment option for nicotine dependence. Dr. Rubinstein is a seasoned medical executive with deep experience in
Filing based on pivotal Phase 3 ORCA-2 and ORCA-3 clinical trials demonstrating statistically significant and clinically meaningful smoking cessation FDA acceptance starts the review process and sets timing for potentially the first new FDA-approved pharmacotherapy in two decadesPDUFA targeted date set for June 20, 2026 SEATTLE and VANCOUVER, British Columbia, Sept. 03, 2025 (GLOBE NEWSWIRE) -- Achieve Life Sciences, Inc. (NASDAQ:ACHV), a late-stage specialty pharmaceutical company focused on the global development and commercialization of cytisinicline for treatment of nicotine dependence, today announced that the U.S. Food and Drug Administration (FDA) has accepted the cytisinicli
3 - ACHIEVE LIFE SCIENCES, INC. (0000949858) (Issuer)
4 - ACHIEVE LIFE SCIENCES, INC. (0000949858) (Issuer)
4 - ACHIEVE LIFE SCIENCES, INC. (0000949858) (Issuer)
H.C. Wainwright initiated coverage of Achieve Life Sciences with a rating of Buy and set a new price target of $12.00
Rodman & Renshaw initiated coverage of Achieve Life Sciences with a rating of Buy and set a new price target of $12.00
Raymond James initiated coverage of Achieve Life Sciences with a rating of Strong Buy and set a new price target of $20.00
4 - ACHIEVE LIFE SCIENCES, INC. (0000949858) (Issuer)
4 - ACHIEVE LIFE SCIENCES, INC. (0000949858) (Issuer)
4 - ACHIEVE LIFE SCIENCES, INC. (0000949858) (Issuer)
SEATTLE and VANCOUVER, British Columbia, July 24, 2025 (GLOBE NEWSWIRE) -- Achieve Life Sciences, Inc. (NASDAQ:ACHV), a late-stage specialty pharmaceutical company focused on the global development and commercialization of cytisinicline as a treatment of nicotine dependence for smoking cessation, today announced it will report its second quarter 2025 financial results and provide a corporate update on the cytisinicline development program on Thursday, August 7, 2025, at 8:30 AM EDT. To access the webcast, please use the following link: 2Q25 Earnings Webcast. Alternatively, you may access the live conference call by dialing 877-269-7756 (U.S. & Canada) or 201-689-7817 (International) and r
Reiterates Planned Submission of an NDA for Cytisinicline to FDA in June 2025 Company to Host Conference Call at 8:30 AM EDT Today, Tuesday, May 13, 2025 SEATTLE and VANCOUVER, British Columbia, May 13, 2025 (GLOBE NEWSWIRE) -- Achieve Life Sciences, Inc. (NASDAQ:ACHV), a late-stage specialty pharmaceutical company focused on the global development and commercialization of cytisinicline as a treatment of nicotine dependence for smoking cessation, today announced its financial results for first quarter 2025 and confirmed that it plans to submit the upcoming New Drug Application (NDA) for cytisinicline to the U.S. Food and Drug Administration (FDA) in June 2025. "The Achieve team is fully
SEATTLE and VANCOUVER, British Columbia, May 06, 2025 (GLOBE NEWSWIRE) -- Achieve Life Sciences, Inc. (NASDAQ:ACHV) a late-stage specialty pharmaceutical company focused on the global development and commercialization of cytisinicline as a treatment of nicotine dependence for smoking cessation, today announced that it will report its first quarter 2025 financial results and provide a corporate update on the cytisinicline development program on Tuesday May 13, 2025, at 8:30 AM EDT. To access the webcast, please use the following link: 1Q25 Earnings Webcast. Alternatively, you may access the live conference call by dialing 877-269-7756 (U.S. & Canada) or 201-689-7817 (International) and r
SEATTLE and VANCOUVER, British Columbia, Jan. 10, 2025 (GLOBE NEWSWIRE) -- Achieve Life Sciences, Inc. (NASDAQ:ACHV), a late-stage pharmaceutical company focused on the global development and commercialization of cytisinicline for smoking cessation and nicotine dependence, today announced that Kristen Slaoui, Ph.D., and Nancy Phelan will join its Board of Directors. Achieve also announced that current Board member, Vaughn Himes, Ph.D., has retired and resigned from the Board. He will continue to provide consulting services to the company. "We are delighted to welcome Kristen and Nancy to our Board of Directors," said Tom King, Executive Chairman of Achieve's Board of Directors. "Their wea
SEATTLE and VANCOUVER, British Columbia, Dec. 09, 2024 (GLOBE NEWSWIRE) -- Achieve Life Sciences, Inc. (NASDAQ:ACHV), a late-stage pharmaceutical company dedicated to the global development and commercialization of cytisinicline for the treatment of nicotine dependence, today announced that Mark Oki has joined the company as its Chief Financial Officer, effective December 5, 2024. Mr. Oki will oversee the company's financial strategy and operations, including accounting, investor relations, information technology, legal and other key administrative functions, ensuring effective planning and execution to support organizational objectives. "Mark's extensive financial, strategic, and opera
Delcath Systems, Inc. (NASDAQ:DCTH) (the "Company" or "Delcath"), an interventional oncology company focused on the treatment of primary and metastatic cancers of the liver, is pleased to announce the appointment of Dr. Bridget Martell to the Company's Board of Directors effective May 23, 2024. "We are pleased to welcome Dr. Martell to the Delcath Board," said John Sylvester, Chairman of the Delcath Board of Directors. "Dr. Martell's extensive experience serving both in senior management roles and as a director at multiple biotechnology companies, as well as her expertise in oncology clinical development, will be a great asset to Delcath as we strive to achieve our mission of improving pa
SC 13G/A - ACHIEVE LIFE SCIENCES, INC. (0000949858) (Subject)
SC 13G - ACHIEVE LIFE SCIENCES, INC. (0000949858) (Subject)
SC 13G/A - ACHIEVE LIFE SCIENCES, INC. (0000949858) (Subject)